Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $17.21

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) shares gapped down before the market opened on Wednesday . The stock had previously closed at $17.21, but opened at $15.54. Y-mAbs Therapeutics shares last traded at $14.48, with a volume of 528,188 shares trading hands.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. HC Wainwright raised their price target on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Wedbush restated an “outperform” rating and issued a $18.00 target price (up from $12.00) on shares of Y-mAbs Therapeutics in a research note on Monday, February 12th. BMO Capital Markets increased their price objective on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an “outperform” rating in a research note on Monday, March 4th. Finally, Canaccord Genuity Group lifted their target price on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat, Y-mAbs Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $16.57.

Y-mAbs Therapeutics Price Performance

The firm has a fifty day moving average of $15.61 and a 200 day moving average of $11.16. The stock has a market capitalization of $564.65 million, a price-to-earnings ratio of -26.27 and a beta of 0.78.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.17. The business had revenue of $23.36 million for the quarter, compared to analysts’ expectations of $21.72 million. Y-mAbs Therapeutics had a negative net margin of 25.26% and a negative return on equity of 20.72%. Research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.43 EPS for the current year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other news, SVP Vignesh Rajah sold 1,711 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $16.53, for a total transaction of $28,282.83. Following the sale, the senior vice president now directly owns 33,889 shares of the company’s stock, valued at approximately $560,185.17. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 21.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. acquired a new position in Y-mAbs Therapeutics during the fourth quarter worth $34,000. Tower Research Capital LLC TRC raised its position in shares of Y-mAbs Therapeutics by 345.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,686 shares of the company’s stock worth $46,000 after purchasing an additional 5,185 shares during the last quarter. Bailard Inc. purchased a new position in Y-mAbs Therapeutics in the 4th quarter valued at about $115,000. SG Americas Securities LLC acquired a new stake in Y-mAbs Therapeutics in the 3rd quarter worth about $100,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Y-mAbs Therapeutics by 4.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,090 shares of the company’s stock worth $178,000 after buying an additional 1,089 shares in the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.